Breast Cancer Assay (HAGE)


The invention relates to a method of identifying aggressive breast cancer tumours by considering the HAGE expression in the tumours.

The invention provides a method of screening breast cancer which comprises testing a sample of breast tissue from a subject for the level of HAGE expression in the sample. The overexpression of HAGE is associated with a more aggressive breast cancer. Moreover, it is possible to articulate a prognosis for the cancer and identify patients who should be clinically treated in a particular way based on the level of HAGE expression in the tumours.

Overexpression of HAGE *(HAGE+) is observed in approx. 10% of BC and it was significantly associated to aggressive clinico-pathological features including ER-, high grade, high proliferation index and triple negative (TNT) phenotypes.

HAGE is an antigenic marker. It may therefore be used as a target therapeutic agent to treat BC by targeting a HAGE CTA antigen.

Benefits and applications

  • Ability to stratify breast cancer patients in order to give them the most appropriate treatment in order to gain maximal clinical benefit and increase the success rate of the therapy.

Contact details

Professor R C Rees
The John Van Geest Cancer Research Centre